Amylin Pharmaceuticals Elects Steven Altman to Board of Directors
March 28 2006 - 8:15AM
PR Newswire (US)
SAN DIEGO, March 28 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that Steven R.
Altman has been elected to the company's Board of Directors
effective immediately. Mr. Altman will serve on Amylin's
Compensation and Human Resources Committee. "We are very pleased to
welcome Steve to the Amylin Board," said Ginger L. Graham,
President and CEO of Amylin Pharmaceuticals. "He helps lead
QUALCOMM Incorporated, a large, global technology business based in
Southern California and brings extensive experience in licensing
and technology acquisitions. He is also a strong patient advocate
with children and other family members living with type 1 diabetes.
Steve has committed personal resources to organizations pursuing
new innovations in diabetes research and has informed us that he
will contribute the compensation he receives from his Amylin board
role to diabetes-related charities." Mr. Altman currently serves as
President of QUALCOMM Incorporated. He joined QUALCOMM in 1989 as
Corporate Counsel responsible for licensing and acquisitions, and
was appointed Vice President and General Counsel in 1992. He became
General Manager of QUALCOMM Technology Licensing (QTL) at the
formation of the group in 1995 and was named Senior Vice President
in 1996. In 1998, Mr. Altman was named Executive Vice President,
then President of QTL in 2000 until his appointment as President of
QUALCOMM in 2005. Mr. Altman began his career with the San Diego
law firm of Gray, Cary, Ware & Freidenrich, where he
specialized in intellectual property, mergers and acquisitions,
securities, and general corporate matters. He graduated from
Northern Arizona University with a bachelor's degree in criminal
justice and received his Juris Doctor from the University of San
Diego School of Law. Mr. Altman is a member of the Board of
Trustees of the Salk Institute. Mr. Altman is also a past board
member of the San Diego chapter of the Juvenile Diabetes Research
Foundation (JDRF) and currently is an active supporter of the JDRF.
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development, and
commercialization of innovative medicines. DATASOURCE: Amylin
Pharmaceuticals, Inc. CONTACT: Alice Bahner, Executive Director,
Investor Relations, Amylin Pharmaceuticals, Inc., +1-858-552-2200
Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024